Does the media refer more to PTGX or NUVB?

In the previous week, Protagonist Therapeutics had 7 more articles in the media than Nuvation Bio. MarketBeat recorded 12 mentions for Protagonist Therapeutics and 5 mentions for Nuvation Bio. Protagonist Therapeutics' average media sentiment score of 0.61 beat Nuvation Bio's score of 0.40 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvation Bio 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, NUVB or PCVX?

Nuvation Bio has higher revenue and earnings than Vaxcyte. Nuvation Bio is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvation Bio $169.90M 12.62 -$204.63M -$0.44 N/A Vaxcyte N/A N/A -$766.63M -$7.63 N/A

Is NUVB or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Vaxcyte's return on equity of -37.56% beat Nuvation Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nuvation Bio -88.18% -46.59% -22.01% Vaxcyte N/A -37.56% -33.62%

Does the media prefer NUVB or PCVX?

In the previous week, Vaxcyte had 11 more articles in the media than Nuvation Bio. MarketBeat recorded 16 mentions for Vaxcyte and 5 mentions for Nuvation Bio. Vaxcyte's average media sentiment score of 0.85 beat Nuvation Bio's score of 0.40 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, NUVB or CYTK?

Nuvation Bio has higher revenue and earnings than Cytokinetics. Nuvation Bio is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvation Bio $169.90M 12.62 -$204.63M -$0.44 N/A Cytokinetics $67.67M 135.65 -$784.96M -$7.22 N/A

Is NUVB or CYTK more profitable?

Nuvation Bio has a net margin of -88.18% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Nuvation Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nuvation Bio -88.18% -46.59% -22.01% Cytokinetics -1,321.12% N/A -51.01%

Does the media prefer NUVB or CYTK?

In the previous week, Cytokinetics had 4 more articles in the media than Nuvation Bio. MarketBeat recorded 9 mentions for Cytokinetics and 5 mentions for Nuvation Bio. Cytokinetics' average media sentiment score of 0.90 beat Nuvation Bio's score of 0.40 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytokinetics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, TGTX or NUVB?

TG Therapeutics has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $616.29M 13.38 $447.18M $2.74 19.67 Nuvation Bio $169.90M 12.62 -$204.63M -$0.44 N/A

Does the media favor TGTX or NUVB?

In the previous week, TG Therapeutics had 4 more articles in the media than Nuvation Bio. MarketBeat recorded 9 mentions for TG Therapeutics and 5 mentions for Nuvation Bio. TG Therapeutics' average media sentiment score of 0.92 beat Nuvation Bio's score of 0.40 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvation Bio 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, IBRX or NUVB?

Nuvation Bio has higher revenue and earnings than ImmunityBio. Nuvation Bio is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $165.79M 50.57 -$351.40M -$0.97 N/A Nuvation Bio $169.90M 12.62 -$204.63M -$0.44 N/A

Does the media refer more to IBRX or NUVB?

In the previous week, ImmunityBio had 2 more articles in the media than Nuvation Bio. MarketBeat recorded 7 mentions for ImmunityBio and 5 mentions for Nuvation Bio. ImmunityBio's average media sentiment score of 0.78 beat Nuvation Bio's score of 0.40 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Nuvation Bio 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Nuvation Bio (NUVB) Competitors

$6.10 -0.18 (-2.79%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$6.08 -0.03 (-0.48%)

As of 09/11/2026 07:54 PM Eastern

Compare

NUVB vs. PTGX, PCVX, CYTK, TGTX, and IBRX

Should you buy Nuvation Bio stock or one of its competitors? Nuvation Bio's main competitors and comparable companies include Protagonist Therapeutics (PTGX), Vaxcyte (PCVX), Cytokinetics (CYTK), TG Therapeutics (TGTX), and ImmunityBio (IBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nuvation Bio compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Nuvation Bio (NYSE:NUVB) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Protagonist Therapeutics presently has a consensus target price of $147.13, indicating a potential downside of 0.71%. Nuvation Bio has a consensus target price of $13.00, indicating a potential upside of 112.94%. Given Nuvation Bio's higher probable upside, analysts clearly believe Nuvation Bio is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Protagonist Therapeutics has a net margin of 29.40% compared to Nuvation Bio's net margin of -88.18%. Protagonist Therapeutics' return on equity of 12.03% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Nuvation Bio	-88.18%	-46.59%	-22.01%

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Protagonist Therapeutics has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	208.36	-$130.15M	$1.03	143.86
Nuvation Bio	$169.90M	12.62	-$204.63M	-$0.44	N/A

In the previous week, Protagonist Therapeutics had 7 more articles in the media than Nuvation Bio. MarketBeat recorded 12 mentions for Protagonist Therapeutics and 5 mentions for Nuvation Bio. Protagonist Therapeutics' average media sentiment score of 0.61 beat Nuvation Bio's score of 0.40 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvation Bio	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protagonist Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Nuvation Bio on 13 of the 16 factors compared between the two stocks.

How does Nuvation Bio compare to Vaxcyte?

Nuvation Bio (NYSE:NUVB) and Vaxcyte (NASDAQ:PCVX) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by insiders. Comparatively, 3.3% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Nuvation Bio presently has a consensus price target of $13.00, indicating a potential upside of 112.94%. Vaxcyte has a consensus price target of $98.00, indicating a potential upside of 64.79%. Given Nuvation Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Nuvation Bio is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Nuvation Bio has higher revenue and earnings than Vaxcyte. Nuvation Bio is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$169.90M	12.62	-$204.63M	-$0.44	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

In the previous week, Vaxcyte had 11 more articles in the media than Nuvation Bio. MarketBeat recorded 16 mentions for Vaxcyte and 5 mentions for Nuvation Bio. Vaxcyte's average media sentiment score of 0.85 beat Nuvation Bio's score of 0.40 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Vaxcyte's return on equity of -37.56% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Vaxcyte	N/A	-37.56%	-33.62%

Nuvation Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

Summary

Nuvation Bio beats Vaxcyte on 9 of the 15 factors compared between the two stocks.

How does Nuvation Bio compare to Cytokinetics?

Nuvation Bio (NYSE:NUVB) and Cytokinetics (NASDAQ:CYTK) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

Nuvation Bio has a net margin of -88.18% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Cytokinetics	-1,321.12%	N/A	-51.01%

Nuvation Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

Nuvation Bio has higher revenue and earnings than Cytokinetics. Nuvation Bio is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$169.90M	12.62	-$204.63M	-$0.44	N/A
Cytokinetics	$67.67M	135.65	-$784.96M	-$7.22	N/A

In the previous week, Cytokinetics had 4 more articles in the media than Nuvation Bio. MarketBeat recorded 9 mentions for Cytokinetics and 5 mentions for Nuvation Bio. Cytokinetics' average media sentiment score of 0.90 beat Nuvation Bio's score of 0.40 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytokinetics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.7% of Nuvation Bio shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Nuvation Bio currently has a consensus target price of $13.00, indicating a potential upside of 112.94%. Cytokinetics has a consensus target price of $103.37, indicating a potential upside of 40.12%. Given Nuvation Bio's higher possible upside, research analysts clearly believe Nuvation Bio is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

Nuvation Bio beats Cytokinetics on 9 of the 16 factors compared between the two stocks.

How does Nuvation Bio compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Nuvation Bio (NYSE:NUVB) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

TG Therapeutics has a net margin of 55.22% compared to Nuvation Bio's net margin of -88.18%. TG Therapeutics' return on equity of 73.49% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Nuvation Bio	-88.18%	-46.59%	-22.01%

TG Therapeutics has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.38	$447.18M	$2.74	19.67
Nuvation Bio	$169.90M	12.62	-$204.63M	-$0.44	N/A

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by company insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, TG Therapeutics had 4 more articles in the media than Nuvation Bio. MarketBeat recorded 9 mentions for TG Therapeutics and 5 mentions for Nuvation Bio. TG Therapeutics' average media sentiment score of 0.92 beat Nuvation Bio's score of 0.40 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvation Bio	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TG Therapeutics presently has a consensus price target of $63.00, indicating a potential upside of 16.90%. Nuvation Bio has a consensus price target of $13.00, indicating a potential upside of 112.94%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Nuvation Bio is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

TG Therapeutics has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

Summary

TG Therapeutics beats Nuvation Bio on 11 of the 16 factors compared between the two stocks.

How does Nuvation Bio compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Nuvation Bio (NYSE:NUVB) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Nuvation Bio has a net margin of -88.18% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Nuvation Bio	-88.18%	-46.59%	-22.01%

ImmunityBio presently has a consensus target price of $14.20, indicating a potential upside of 79.52%. Nuvation Bio has a consensus target price of $13.00, indicating a potential upside of 112.94%. Given Nuvation Bio's higher possible upside, analysts clearly believe Nuvation Bio is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 66.1% of ImmunityBio shares are held by insiders. Comparatively, 30.1% of Nuvation Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, ImmunityBio had 2 more articles in the media than Nuvation Bio. MarketBeat recorded 7 mentions for ImmunityBio and 5 mentions for Nuvation Bio. ImmunityBio's average media sentiment score of 0.78 beat Nuvation Bio's score of 0.40 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Nuvation Bio	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvation Bio has higher revenue and earnings than ImmunityBio. Nuvation Bio is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$165.79M	50.57	-$351.40M	-$0.97	N/A
Nuvation Bio	$169.90M	12.62	-$204.63M	-$0.44	N/A

ImmunityBio has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

Summary

Nuvation Bio beats ImmunityBio on 9 of the 16 factors compared between the two stocks.

Get Nuvation Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUVB vs. The Competition

Export

Metric	Nuvation Bio	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$2.21B	$3.86B	$7.17B	$23.20B
Dividend Yield	N/A	3.63%	2.56%	3.56%
P/E Ratio	-13.88	14.18	273.82	28.71
Price / Sales	12.62	1,486.37	656.53	94.63
Price / Cash	N/A	106.68	77.04	33.82
Price / Book	6.94	15.12	10.33	4.74
Net Income	-$204.63M	-$22.86M	$3.50B	$1.07B
7 Day Performance	-10.09%	-4.32%	-3.33%	-2.00%
1 Month Performance	-4.91%	-0.01%	-0.42%	-2.68%
1 Year Performance	94.43%	40.62%	19.21%	10.45%

Nuvation Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUVB Nuvation Bio	2.679 of 5 stars	$6.11 -2.8%	$13.00 +112.9%	+82.2%	$2.21B	$169.90M	N/A	305
PTGX Protagonist Therapeutics	1.5511 of 5 stars	$145.72 flat	$147.13 +1.0%	+148.3%	$9.43B	$46.02M	141.48	120	Insider Trade
PCVX Vaxcyte	2.1835 of 5 stars	$61.16 flat	$86.00 +40.6%	+79.9%	$9.10B	N/A	N/A	160	Options Volume
CYTK Cytokinetics	2.7431 of 5 stars	$72.72 flat	$103.37 +42.1%	+38.4%	$9.05B	$88.04M	N/A	250	Analyst Forecast Insider Trade
TGTX TG Therapeutics	3.3937 of 5 stars	$55.99 flat	$63.00 +12.5%	+66.0%	$8.57B	$616.29M	20.43	290

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NUVB) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvation Bio (NUVB) Competitors

NUVB vs. PTGX, PCVX, CYTK, TGTX, and IBRX

How does Nuvation Bio compare to Protagonist Therapeutics?

Summary

How does Nuvation Bio compare to Vaxcyte?

Summary

How does Nuvation Bio compare to Cytokinetics?

Summary

How does Nuvation Bio compare to TG Therapeutics?

Summary

How does Nuvation Bio compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB vs. The Competition

Nuvation Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvation Bio (NUVB) Competitors

NUVB vs. PTGX, PCVX, CYTK, TGTX, and IBRX

How does Nuvation Bio compare to Protagonist Therapeutics?

Do analysts recommend PTGX or NUVB?

Is PTGX or NUVB more profitable?

Do insiders & institutionals have more ownership in PTGX or NUVB?

Which has higher earnings & valuation, PTGX or NUVB?

Does the media refer more to PTGX or NUVB?

Which has more risk and volatility, PTGX or NUVB?

Summary

How does Nuvation Bio compare to Vaxcyte?

Do insiders & institutionals believe in NUVB or PCVX?

Do analysts rate NUVB or PCVX?

Which has higher valuation and earnings, NUVB or PCVX?

Does the media prefer NUVB or PCVX?

Is NUVB or PCVX more profitable?

Which has more volatility and risk, NUVB or PCVX?

Summary

How does Nuvation Bio compare to Cytokinetics?

Is NUVB or CYTK more profitable?

Which has more risk & volatility, NUVB or CYTK?

Which has preferable earnings & valuation, NUVB or CYTK?

Does the media prefer NUVB or CYTK?

Do insiders and institutionals believe in NUVB or CYTK?

Do analysts rate NUVB or CYTK?

Summary

How does Nuvation Bio compare to TG Therapeutics?

Is TGTX or NUVB more profitable?

Which has stronger valuation & earnings, TGTX or NUVB?

Do institutionals & insiders believe in TGTX or NUVB?

Does the media favor TGTX or NUVB?

Do analysts rate TGTX or NUVB?

Which has more risk and volatility, TGTX or NUVB?

Summary

How does Nuvation Bio compare to ImmunityBio?

Is IBRX or NUVB more profitable?

Do analysts prefer IBRX or NUVB?

Do institutionals and insiders have more ownership in IBRX or NUVB?

Does the media refer more to IBRX or NUVB?

Which has higher valuation & earnings, IBRX or NUVB?

Which has more volatility & risk, IBRX or NUVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB vs. The Competition

Nuvation Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools